Research progress of β-adrenergic receptor antagonists in the treatment of ocular neovascular diseases
10.3760/cma.j.cn511434-20210203-00063
- VernacularTitle:β肾上腺素能受体拮抗剂治疗眼部新生血管疾病的研究进展
- Author:
Ru ZHAO
1
;
Jinyuan LUO
;
Tao HE
;
Yiqiao XING
Author Information
1. 武汉大学人民医院眼科中心，武汉 430060
- Keywords:
Adrenergic beta-antagonists;
Corneal neovascularization;
Retinal neovascularization;
Choroidal neovascularization;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2022;38(4):330-333
- CountryChina
- Language:Chinese
-
Abstract:
Ocular neovascularization is a pathological change in various ocular diseases such as diabetic retinopathy, retinopathy of prematurity, central retinal vein occlusion and age-related macular degeneration, which seriously affects patient's vision. β receptors are expressed in conjunctiva, corneal epithelial cells, corneal endothelial cells, extraocular muscles, trabecular meshwork, ciliary muscle, lens and retina. β adrenergic receptor antagonists bind to β receptors to exert anti-angiogenic effects by inhibiting the expression of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, interleukin-6 and other angiogenic cytokines; reducing macrophage-related inflammatory response; increasing the expression of anti-angiogenic factors. In the treatment of corneal neovascularization, choroidal neovascularization, and retinopathy of prematurity, it can significantly reduce the area of neovascularization and delay disease progression. Co-administration of anti-VEGF drugs can reduce the frequency of administration of anti-VEGF drugs. At effective therapeutic concentrations, β-adrenergic receptor antagonists are well tolerated; they have broader targets than anti-VEGF drugs, which offers new treatment strategies for ocular neovascularization such as corneal, choroidal and retinal neovascularization.
